WeTrials
Active, not recruiting

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

What is this study?

This study is testing an experimental medication called marlotamig, both by itself and combined with other cancer treatments like cemiplimab and chemotherapy. Researchers want to find the safest and most effective doses to help shrink advanced solid tumors.

Who can participate?

You might be able to join if you have a confirmed advanced cancer diagnosis, are able to carry out light daily activities, and meet specific treatment history requirements. Your doctors will also need to check that you have a measurable area of cancer and are willing to provide a new tumor tissue sample.

What will happen?

Participants will receive the study medications and be closely monitored for side effects and how the drugs work in the body. This involves regular health checks, blood tests, and tracking how your tumor responds to the treatment.

Where and when?

The study has locations in places like Los Angeles and San Francisco, California. It is currently active, which means ongoing care is happening for enrolled participants, though it is not actively looking for new patients right now.

Key Points
  • 1Tests the new drug marlotamig alone and with other cancer therapies
  • 2Focuses on finding the right dose and checking for side effects
  • 3Currently active but not recruiting new participants

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.